Intensive Induction Chemotherapy (IC) Vs Hypomethylating Agents plus Venetoclax (HMA/VEN) in IDH1-or IDH2-Mutant Newly Diagnosed Acute Myeloid Leukemia ( AML) - a Multicenter Cohort Study

被引：0
|
作者：
Bewersdorf, Jan Philipp [1 ]
Shimony, Shai [2 ]
Shallis, Rory M. [3 ]
Liu, Yiwen [4 ]
Schaefer, Eva Johanna [5 ]
Zeidan, Amer M. [6 ,7 ]
Goldberg, Aaron D. [1 ]
Stein, Eytan M. [1 ]
Marcucci, Guido [8 ]
Lindsley, R. Coleman [9 ]
Chen, Evan C. [5 ]
Ramos, Jorge [10 ]
Stein, Anthony Selwyn [11 ]
DeAngelo, Daniel J. [12 ]
Neuberg, Donna S. [4 ]
Stone, Richard M. [12 ]
Ball, Brian J. [10 ]
Stahl, Maximilian [13 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY USA
[2] Harvard Med Sch, DanaFarber Canc Inst, Dept Med Oncol, Boston, MA USA
[3] Yale Univ, Sect Hematol, Dept Internal Med, Yale Sch Med, New Haven, CT USA
[4] DanaFarber Canc Inst, Dept Data Sci, Boston, MA USA
[5] Dana Farber Canc Inst, Med Oncol, Boston, MA USA
[6] Yale Univ, Dept Internal Med, Yale Sch Med, New Haven, CT USA
[7] Yale Univ, Yale Canc Ctr, New Haven, CT USA
[8] City Hope Natl Med Ctr & Beckman Res Inst, Dept Hematol Malignancies Translat Sci, Gehr Family Ctr Leukemia Res, Duarte, CA USA
[9] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA
[10] City Hope Canc Ctr, Duarte, CA USA
[11] City Hope Natl Med Ctr, Duarte, CA USA
[12] Dana Farber Canc Inst, Boston, MA USA
[13] Dana Farber Inst, Boston, MA USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-174283
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [31] Outcome of Newly Diagnosed Acute Myeloid Leukemia (AML) Refractory to 1 or 2 Cycles of Induction Chemotherapy
    Zarzour, Ahmad
    Nazha, Aziz
    Kalaycio, Matt
    Patel, Bhumika J.
    Gerds, Aaron T.
    Clemente, Michael J.
    Hirsch, Cassandra M.
    Carew, Jennifer S.
    Advani, Anjali S.
    Sanikommu, Srinivasa R.
    Przychodzen, Bartlomiej
    Carraway, Hetty E.
    Mukherjee, Sudipto
    Maciejewski, Jaroslaw P.
    Sekeres, Mikkael A.
    BLOOD, 2015, 126 (23)
  • [32] Venetoclax Combined with Homoharringtonine and Cytarabine (HAV) As Induction Treatment in Elder or Intensive Chemotherapy (IC) Ineligible Patients with Newly Diagnosed Acute Myeloid Leukemia
    Liu, Kaiqi
    Suo, Xiaohui
    Bai, Guanchen
    Yan, Zhangsong
    Li, Yang
    Zhang, Bin
    He, Jinsong
    Wei, Shuning
    Li, Qiuling
    Hu, Bo
    Mi, Yingchang
    BLOOD, 2023, 142
  • [33] Intensive induction chemotherapy vs hypomethylating agent-based regimen in patients aged ≥70 years with newly diagnosed acute myeloid leukemia
    Lim, Matthew J.
    Agha, Aya
    Im, Annie
    Raptis, Anastasios
    Hou, Jing Z.
    Boyiadzis, Michael
    Sehgal, Alison R.
    Redner, Robert L.
    Dorritie, Kathleen
    Marks, Stanley S.
    Agha, Mounzer E.
    Lim, Seah H.
    HEMATOLOGICAL ONCOLOGY, 2018, 36 (02) : 495 - 497
  • [34] Outcomes of Newly Diagnosed Acute Myeloid Leukemia Patients Treated With Hypomethylating Agents With or Without Venetoclax: A Propensity Score-Adjusted Cohort Study
    Mustafa Ali, Moaath K.
    Corley, Elizabeth M.
    Alharthy, Hanan
    Kline, Kathryn A. F.
    Law, Jennie Y.
    Lee, Seung Tae
    Niyongere, Sandrine
    Duong, Vu H.
    Emadi, Ashkan
    Baer, Maria R.
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [35] Low dose venetoclax plus itraconazole outpatient induction in newly diagnosed acute myeloid leukemia: A phase 2 study
    De la Garza-Salazar, Fernando
    Colunga-Pedraza, Perla Rocio
    Gomez-Almaguer, David
    Garcia-Zarate, Valeria Abigail
    Gomez-De Leon, Andres
    LEUKEMIA RESEARCH, 2023, 133
  • [36] Intensive Chemotherapy vs. Hypomethylating Agents in Older Adults with Newly Diagnosed High-Risk Acute Myeloid Leukemia: A Single Center Experience
    Vachhani, Pankit
    Al Yacoub, Raed
    Miller, Austin
    Cronin, Tara
    Ontiveros, Evelena
    Thompson, James
    Griffiths, Elizabeth
    Wang, Eunice
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S288 - S289
  • [37] Intensive chemotherapy vs. hypomethylating agents in older adults with newly diagnosed high-risk acute myeloid leukemia: A single center experience
    Vachhani, Pankit
    Al Yacoub, Raed
    Miller, Austin
    Zhang, Fan
    Cronin, Tara L.
    Ontiveros, Evelena P.
    Thompson, James E.
    Griffiths, Elizabeth A.
    Wang, Eunice S.
    LEUKEMIA RESEARCH, 2018, 75 : 29 - 35
  • [38] Intensive Chemotherapy Vs. Hypomethylating Agents in Older Adults with Newly Diagnosed High-Risk Acute Myeloid Leukemia: A Single Center Experience
    Vachhani, Pankit
    Al Yacoub, Raed
    Miller, Austin
    Cronin, Tara
    Ontiveros, Evelena P.
    Thompson, James E.
    Griffiths, Elizabeth A.
    Wang, Eunice S.
    BLOOD, 2017, 130
  • [39] Mutant IDH1 Inhibitor Ivosidenib (IVO; AG-120) in Combination with Azacitidine (AZA) for Newly Diagnosed Acute Myeloid Leukemia (ND AML)
    DiNardo, Courtney D.
    Stein, Anthony S.
    Stein, Eytan M.
    Fathi, Amir T.
    Frankfurt, Olga
    Schuh, Andre C.
    Doehner, Hartmut
    Martinelli, Giovanni
    Raffoux, Emmanuel
    Tan, Peter
    Zeidan, Amer
    de Botton, Stephane
    Kantarjian, Hagop M.
    Stone, Richard M.
    Lam, Du
    Wang, Xiwei
    Gong, Jing
    Kapsalis, Stephanie M.
    Hickman, Denice
    Zhang, Vickie
    Winkler, Thomas
    Daigle, Scott
    Vyas, Paresh
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S217 - S218
  • [40] Mutant IDH1 inhibitor ivosidenib (IVO; AG-120) in combination with azacitidine (AZA) for newly diagnosed acute myeloid leukemia (ND AML).
    Dinardo, Courtney Denton
    Stein, Anthony Selwyn
    Stein, Eytan M.
    Fathi, Amir Tahmasb
    Frankfurt, Olga
    Schuh, Andre C.
    Martinelli, Giovanni
    Patel, Prapti Arvind
    Raffoux, Emmanuel
    Tan, Peter
    Zeidan, Amer Methqal
    de Botton, Stephane
    Kantarjian, Hagop M.
    Stone, Richard M.
    Lam, Du Hung
    Gong, Jing
    Zhang, Vickie
    Winkler, Thomas
    Wu, Bin
    Vyas, Paresh
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345